High CD133 expression levels in gastrointestinal stromal tumors
Open Access
- 15 March 2011
- journal article
- research article
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 80B (4) , 238-247
Abstract
Background: Gastrointestinal stromal tumours (GISTs) have activating KIT or PDGFRA gene mutations. Imatinib mesylate, which targets KIT and PDGFRA, is effective in treating GISTs, but 90% of GIST patients become imatinib‐resistant as a result of acquiring secondary KIT mutations. Recent findings suggest that tumour growth can be driven by mutated self‐renewing progenitors known as cancer stem cells (CSCs), which are believed to be present in all neoplastic proliferations and are thought to accumulate mutations. It is therefore possible that the acquisition of secondary KIT mutations during imatinib treatment may occur in putative GIST CSCs. Methods: Using flow cytometry, in vivo murine xenografts and molecular characterization, we tried to identify putative GIST CSCs by looking for the occurrence of common CSC markers such as KIT, CD133, CD90, CD44, and CD34 in 18 surgical samples obtained from nine untreated and nine imatinib‐treated KIT‐mutated GIST patients. Results: The results indicated the homogeneous and previously unreported expression of CD133 (18/18), CD90 (15/16), and CD44 (12/14), together with KIT (18/18) and CD34 (13/18). This profile is similar to that identified in bone marrow mesenchymal progenitors and does not seem to be significantly modified by imatinib as only marginal changes in KIT and CD133 expression (P ≤0.05, Mann‐Whitney test) were found in the treated samples. Conclusions: These findings suggest that GISTs are a clonal expansion of quite primitive cells that strictly depend on KIT oncogenic addiction, and have no cancer/stem cell component that can be detected by means of the antigens used in this study. © 2011 International Clinical Cytometry SocietyKeywords
This publication has 35 references indexed in Scilit:
- BRAFMutation Status in Gastrointestinal Stromal TumorsAmerican Journal of Clinical Pathology, 2010
- Neurofibromatosis type 1 and associated malignanciesCurrent Neurology and Neuroscience Reports, 2009
- Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GroupJournal of Clinical Oncology, 2008
- Distinct Gene Expression–Defined Classes of Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2008
- Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumorsProceedings of the National Academy of Sciences, 2008
- Heterogeneity of kinase inhibitor resistance mechanisms in GISTThe Journal of Pathology, 2008
- Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: Report of 220 tumors and review of literatureGenes, Chromosomes and Cancer, 2007
- Recent advances in the understanding of mastocytosis: the role of KIT mutations*British Journal of Haematology, 2007
- A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumorsOncogene, 2007
- Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patientsOncogene, 2006